Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses

  24 October 2024

Antimicrobial resistance is a global health concern, particularly among children under five. It requires a comprehensive approach, including infection prevention, surveillance, stewardship, therapy appropriateness, and research. However, research in this field is limited, lags behind other fields like cancer or HIV. The 2023 WHO analysis of the global antibacterial clinical pipeline highlights gaps in developing a robust drug pipeline. The analysis evaluates antibiotic activity against the new WHO bacterial priority pathogens list 2024, highlighting changing resistance patterns and new resistance mechanisms.

Further reading: The Lancet Microbe
Author(s): Daniela Melchiorri et al
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed